Short Interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Decreases By 9.1%

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totalling 15,720,000 shares, a decrease of 9.1% from the December 15th total of 17,290,000 shares. Based on an average daily volume of 2,050,000 shares, the days-to-cover ratio is presently 7.7 days.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on BCRX shares. Barclays upped their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Needham & Company LLC upped their target price on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, Evercore ISI upped their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $15.17.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock traded up $0.39 during trading hours on Friday, reaching $7.45. The company had a trading volume of 3,962,956 shares, compared to its average volume of 1,628,471. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $8.88. The company has a 50-day moving average price of $7.57 and a 200 day moving average price of $7.62.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. The company’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.19) earnings per share. Analysts forecast that BioCryst Pharmaceuticals will post -0.38 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Rhumbline Advisers raised its holdings in shares of BioCryst Pharmaceuticals by 6.3% during the second quarter. Rhumbline Advisers now owns 318,665 shares of the biotechnology company’s stock valued at $1,969,000 after acquiring an additional 18,916 shares in the last quarter. American Century Companies Inc. raised its holdings in BioCryst Pharmaceuticals by 896.6% in the 2nd quarter. American Century Companies Inc. now owns 148,490 shares of the biotechnology company’s stock worth $918,000 after purchasing an additional 133,591 shares in the last quarter. Hsbc Holdings PLC lifted its position in shares of BioCryst Pharmaceuticals by 32.7% in the 2nd quarter. Hsbc Holdings PLC now owns 125,004 shares of the biotechnology company’s stock worth $759,000 after purchasing an additional 30,788 shares during the period. Seven Eight Capital LP boosted its stake in shares of BioCryst Pharmaceuticals by 1,407.1% during the 2nd quarter. Seven Eight Capital LP now owns 169,612 shares of the biotechnology company’s stock valued at $1,048,000 after purchasing an additional 158,358 shares in the last quarter. Finally, XTX Topco Ltd increased its position in shares of BioCryst Pharmaceuticals by 299.0% during the second quarter. XTX Topco Ltd now owns 156,946 shares of the biotechnology company’s stock valued at $970,000 after buying an additional 117,607 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.